Dermata Therapeutics, Inc.
Business
Dermata Therapeutics is a skincare company developing and commercializing direct-to-consumer and business-to-business cosmetic and over-the-counter skincare products. The company's primary offering is its proprietary Bioneedle technology derived from Spongilla lacustris, a freshwater sponge ingredient, incorporated into multiple product lines. Dermata markets its Tome skincare brand through dual channels: direct e-commerce sales to consumers and professional partnerships with aestheticians and dermatologists, with initial product launches planned for mid-2026.
Summary from 10-K filed 2026-03-26
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 3 | 8 | 4 | 6 | 3 | |
| Selling, general and administrative (including related party amounts of $645,250 and $0, respectively) | 5 | 4 | — | — | — | |
| Total operating expenses | 8 | 13 | 8 | 10 | — | |
| Loss from operations | −8 | −13 | −8 | −10 | −8 | |
| Interest income | 215,041 | 225,781 | — | — | — | |
| Net loss | −8 | −12 | −8 | −10 | −8 | |
| Net loss per share of Common Stock, basic | −8.16 | −80.32 | — | −0.87 | −2.43 | |
| Net loss per share of Common Stock, diluted | −8.16 | −80.32 | −39.99 | — | — | |
| Weighted-average basic Common Stock | 926,192 | 152,974 | — | — | 4 | |
| Weighted-average diluted Common Stock | 926,192 | 152,974 | 194,928 | — | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 8 | 3 | — | 6 | 11 | |
| Prepaid expenses and other current assets | 341,848 | 372,318 | 540,499 | 703,194 | 825,134 | |
| Total assets | 8 | 4 | 8 | 7 | 12 | |
| Accounts payable (including related party amounts of $86,250 and $0, respectively) | 460,811 | 808,011 | 866,028 | 496,702 | 515,245 | |
| Accrued and other current liabilities (including related party amounts of $25,000 and $0, respectively) | 1 | 1 | 757,588 | 425,932 | — | |
| Total liabilities | 2 | 2 | 2 | 922,634 | 2 | |
| Commitments and Contingencies (see Note 7) | — | — | — | — | — | |
| Common Stock, par value $0.0001, 250,000,000 shares authorized as of December 31, 2025, and 2024; 2,660,110 and 251,725 shares issued and outstanding as of December 31, 2025, and 2024, respectively. | 266 | 25 | 26 | 77 | 833 | |
| Additional paid-in capital | 79 | 67 | 60 | 52 | 46 | |
| Accumulated deficit | −73 | −66 | −53 | −46 | −36 | |
| Total stockholders equity | 6 | 2 | 6 | 6 | 10 | |
| Total liabilities and stockholders equity | 8 | 4 | 8 | 7 | 12 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Stock-based compensation | 143,732 | 657,649 | 522,082 | 930,325 | 2 | |
| Prepaid expenses and other current assets | 30,470 | 168,181 | 162,695 | 121,940 | — | |
| Accounts payable | −388,056 | −108,512 | 369,326 | −18,543 | 410,969 | |
| Accrued and other current liabilities | 14,852 | 407,195 | — | — | — | |
| Net cash used in operating activities | −8 | −11 | −6 | −9 | −6 | |
| Proceeds from issuance of Common Stock, pre-funded warrants, and warrants, net of issuance costs | 12 | 7 | 8 | 4 | 15 | |
| Payment of prior period issuance costs | −50,495 | — | — | — | — | |
| Proceeds from exercise of pre-funded warrants | 977 | 1,109 | 187 | 287 | — | |
| Payment for fractional shares in reverse stock split | −367 | −828 | −40 | 0 | — | |
| Net cash provided by financing activities | 12 | 7 | 8 | 4 | 16 | |
| Net increase (decrease) in cash and cash equivalents | 4 | −4 | — | — | 10 | |
| Cash paid for taxes | 950 | 950 | 950 | 950 | 1,400 | |
| Issuance of abeyance shares | — | −18 | 0 | — | — | |
| Issuance costs in accounts payable or accrued expenses | 91,352 | 50,495 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Dermata Therapeutics, Inc.'s CIK number?
Dermata Therapeutics, Inc.'s SEC CIK number is 0001853816 (1853816). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Dermata Therapeutics, Inc.'s SEC filings?
All of Dermata Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Dermata Therapeutics, Inc. last report earnings?
Dermata Therapeutics, Inc. (DRMA) most recently filed an earnings 8-K with the SEC on May 13, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001493152-26-022710). This is Dermata Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Dermata Therapeutics, Inc.'s most recent earnings 8-K?
Dermata Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 13, 2026 under accession 0001493152-26-022710. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Dermata Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →